QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Amivantamab Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Amivantamab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which patient characteristic is most important to retain when defining the treatment context for an amivantamab safety case?

The patient's blood group only The exact EGFR alteration The date of the patient's first chest radiograph only The tumour's histological grade without molecular information

Question 2 of 10 Which principle is most appropriate when assessing hepatic laboratory abnormalities during multidrug therapy?

Attribute every abnormality to amivantamab because it is the targeted medicine Review baseline and serial tests together with concomitant medicines, liver disease, metastases and response to treatment modification Ignore bilirubin and alkaline phosphatase because only transaminases are informative Use a single isolated laboratory value as definitive proof of causality

Question 3 of 10 Which dataset would best support assessment of a suspected chemotherapy-associated cytopenia during amivantamab treatment?

Baseline counts, nadir, cycle-level timing, febrile or bleeding complications, transfusions and growth-factor use Only the date on which the cancer was diagnosed Only the patient's EGFR mutation without blood-count data Only the route of amivantamab administration

Question 4 of 10 Why should exon 20 insertion disease not be treated as interchangeable with exon 19 deletion or exon 21 L858R disease in aggregate pharmacovigilance analyses?

The mutation subtype can define different treatment settings, prior therapies and combination regimens Mutation subtype changes the batch number of the product All EGFR mutations have identical treatment histories and toxicity profiles Exon 20 insertion disease is unrelated to EGFR signalling

Question 5 of 10 Why should subcutaneous injection-site reactions be analysed separately from intravenous administration reactions?

They are always caused by a different active substance They arise in different administration contexts and require different prevention, management and operational controls Subcutaneous administration cannot cause any local reaction Intravenous and subcutaneous records are legally prohibited from being compared

Question 6 of 10 Why is MET biologically relevant when assessing amivantamab treatment in EGFR-mutant NSCLC?

MET is the only receptor responsible for EGFR mutation testing MET signalling can support tumour growth and provide a bypass pathway during EGFR-directed treatment MET determines whether a patient has an infusion reaction MET is a chemotherapy agent routinely combined with amivantamab

Question 7 of 10 Which case description provides the most complete exposure context for amivantamab?

NSCLC treated with amivantamab; patient developed dyspnoea EGFR exon 20 insertion-positive NSCLC, amivantamab monotherapy after platinum failure, intravenous administration, reaction during dose two, with premedication and infusion interruption documented Lung cancer with an adverse event; product batch unavailable EGFR-mutant cancer treated with an unspecified antibody and an unspecified combination

Question 8 of 10 Which statement best describes the role of current EU product information in amivantamab pharmacovigilance?

It defines relevant authorised molecular settings, combinations, administration requirements, prophylaxis and dose-modification considerations It is needed only to determine the product colour It can be replaced by historical trial protocols for current case assessment It has no relevance to route-specific safety monitoring

Question 9 of 10 Which set of mechanisms most appropriately describes how amivantamab may produce antitumour activity?

DNA alkylation, ribosomal inhibition and renal tubular secretion Ligand-signalling blockade, receptor internalisation or downmodulation, and Fc-mediated immune-effector activity Selective inhibition of tumour angiogenesis without receptor binding Direct destruction of tumour DNA by a platinum-like mechanism

Question 10 of 10 Which follow-up information would add the most clinical value to a report initially described only as 'rash'?

Morphology, distribution, nail involvement, secondary infection, treatment and dose modification The patient's blood group and vaccination history only The number of imaging scans performed before diagnosis The product batch number without any clinical description

Professional Knowledge Assessment: Amivantamab Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings